Manufacturing Execution System im Biowissenschaftsmarkt – Erkenntnisse aus globaler und regionaler Analyse – Prognose bis 2031

  • Report Code : TIPRE00029831
  • Category : Technology, Media and Telecommunications
  • Status : Published
  • No. of Pages : 214
Buy Now

Das Manufacturing Execution System im Biowissenschaftsmarkt soll bis 2033 einen Wert von 10.456,54 Millionen US-Dollar erreichen, gegenüber 3.139,14 Millionen US-Dollar im Jahr 2022; Es wird erwartet, dass es zwischen 2023 und 2033 mit einer jährlichen Wachstumsrate von 12,0 % wachsen wird.



Das Manufacturing Execution System (MES) ist eine umfassende, dynamische Lösung, die dabei hilft, den Warenprozess zu verfolgen, zu überwachen, zu dokumentieren und zu steuern Herstellung, vom Rohstoff bis zum fertigen Produkt. Diese Lösungen stellen Entscheidungsträgern auch multivariate Daten zur Verfügung, die zur Optimierung des Fabrikbetriebs und zur Steigerung der Produktionseffizienz genutzt werden können. Darüber hinaus hilft die Implementierung eines MES in pharmazeutischen Produktionsanlagen Herstellern, die Planung und Ressourcennutzung zu verbessern, die Fertigungsflexibilität und Prozessumstellung zu verbessern, die laufenden Arbeiten (WIP) zu reduzieren, die Materialverfolgung zu verbessern, Produktionszyklen zu verkürzen, Produktionsaufzeichnungsfehler zu reduzieren und Produktrückrufe zu minimieren .



Manufacturing Execution System im Life-Science-Markt – Strategische Erkenntnisse



Steigerung der Akzeptanz von Pharma 4.0 treibt das Wachstum des Manufacturing Execution-Systems im Life-Science-Markt voran



Die zunehmende Digitalisierung In der Pharmaindustrie steigt die Nachfrage nach Pharma 4.0. Einer der Faktoren, die zur wachsenden Größe des Manufacturing Execution Systems im Life-Science-Markt beitragen. Das Modell trägt dazu bei, die Konnektivität und Produktivität zu erhöhen, die Einhaltung von Vorschriften zu vereinfachen und Produktionsinformationen zu bündeln, um auf auftretende Probleme reagieren zu können. Das Pharma 4.0-Modell trägt dazu bei, den Herstellungsprozess zu transformieren, indem es die Mitarbeiter in stärker auf den Menschen ausgerichtete Arbeitsabläufe einbindet. Die International Society for Pharmaceutical Engineering (ISPE) und ihre Mitglieder entwickeln einen Fahrplan zur Einführung von Pharma 4.0. Das Ziel des Pharma 4.0-Modells besteht darin, Organisationen in die Lage zu versetzen, das volle Potenzial der Digitalisierung auszuschöpfen, um schnellere therapeutische Innovationen bereitzustellen und Produktionsprozesse für Patienten zu verbessern. Nutzen.



Die wichtigsten Akteure im Pharma 4.0-Ökosystem arbeiten zusammen, um die Einführung desselben zu beschleunigen. Beispielsweise gaben Lonza und NNIT im März 2021 eine Partnerschaft zur Beschleunigung von MES-Projekten bekannt. Im Rahmen dieser Partnerschaft werden die Unternehmen die MODA-Plattform von Lonza mit der Accelerated Implementation Methodology von NNIT kombinieren. Damit erhalten die Unternehmen eine komplette Pharma 4.0-Lösung und können ihre Digitalisierungsvision schneller als je zuvor verwirklichen. Daher steigert die zunehmende Einführung von Pharma 4.0 das Wachstum des Manufacturing Execution Systems im Life-Science-Markt.



Lukrative Regionen für das Manufacturing Execution System im Life-Science-Markt







Markteinblicke – Manufacturing Execution System im Life Sciences-Markt



Basierend auf der Region wird der Markt für Manufacturing Execution Systems in Nordamerika, Europa, den asiatisch-pazifischen Raum, Südamerika sowie den Nahen Osten und andere Regionen eingeteilt. Afrika. Nordamerika dominierte im Jahr 2022 das Manufacturing Execution System im Marktanteil der Biowissenschaften. Der Markt in dieser Region ist weiter in die USA, Kanada und Mexiko unterteilt. Nordamerika gehört zu den entwickelten Regionen. Pharmazie, Biotechnologie und viele andere Branchen in der Region sind für die Einführung hochentwickelter Technologien und automatisierter Abläufe bekannt. Pharma-, Medizingeräte- und Biotechnologieunternehmen implementieren MES, um die Produktivität und das Management ihrer Produktionseinheiten zu verbessern. Unternehmen wie Abbot, Baxter International, Genitope Corporation und Merck & Co. Daher wird erwartet, dass die zunehmende Einführung der digitalen Transformation in den kommenden Jahren die Größe des Manufacturing Execution Systems im Life-Science-Markt in Nordamerika steigern wird.



Bereitstellungsbasierte Einblicke



The Das Manufacturing Execution System im Life-Science-Markt ist je nach Bereitstellung in Cloud und On-Premise unterteilt. Das On-Premise-Segment hielt im Jahr 2022 den größeren Marktanteil von Manufacturing Execution Systemen im Life-Science-Bereich, aber das Cloud-Segment wird im Prognosezeitraum voraussichtlich eine höhere CAGR verzeichnen. Das Cloud-Segment wächst aufgrund mehrerer vorteilhafter Eigenschaften wie Skalierbarkeit und Kosteneffizienz erheblich. Cloud Native MES werden in Form einer Software-as-a-Service (SaaS)-Lösung angeboten, die über das Internet läuft. Solche MES-Lösungen ermöglichen allen beteiligten Mitarbeitern den Zugriff auf Echtzeit-Aufgaben, die jederzeit ausgeführt werden können. Mit der zunehmenden Einführung von Pharma 4.0 verzeichnen Pharmaunternehmen einen schnellen Übergang zu cloudbasierten Lösungen. Auch große MES-Anbieter unternehmen Schritte, um diesen Wandel zu fördern und zu unterstützen. Im Februar 2023 gab General Electric die Aufnahme cloudbasierter MES-Software in das „Proficy Smart Factory Portfolio“ bekannt.



Das Manufacturing Execution System im Life-Science-Markt ist nach Angebot, Bereitstellung und Organisation segmentiert Größe und Anwendung. Basierend auf dem Angebot ist das Manufacturing Execution System im Life-Science-Markt in Software und Dienstleistungen unterteilt. Hinsichtlich der Bereitstellung ist das Manufacturing Execution System im Life-Science-Markt in On-Premise und Cloud unterteilt. Je nach Organisationsgröße ist das Manufacturing Execution System im Life-Science-Markt in KMU und Großunternehmen unterteilt. Basierend auf der Anwendung wird das Manufacturing Execution System im Life-Science-Markt in Pharma-, Biotechnologie- und Medizingeräte unterteilt. Basierend auf der geografischen Lage ist das Manufacturing Execution System im Life-Science-Markt hauptsächlich in Nordamerika, Europa, den asiatisch-pazifischen Raum (APAC), den Nahen Osten und die USA unterteilt. Afrika (MEA) und Südamerika (SAM).



Korber AG, Siemens AG, General Electric, Emerson Electric, Schneider, Rockwell Automation, Apprentice FS Inc, ATS Global, Atachi Systems, LZ Lifescience Ltd, POMS Corporation und Schneider Electric gehören zu den Hauptakteuren im Bereich Manufacturing Execution System im Life-Science-Markt.



Die Player im Bereich Manufacturing Execution System im Life-Science-Markt konzentrieren sich hauptsächlich auf Partnerschaften zur Schaffung von Kundennutzen.



< ul>
  • Im Mai 2022 gab Eyelita, Anbieter von Manufacturing Execution (MES), Qualitätsmanagementsystemen (QMS) und Fabrikautomatisierungslösungen, die Übernahme von MESTEC bekannt, einem in Großbritannien ansässigen Anbieter von Software as a Service (SaaS) für die Fertigung. Die Partnerschaft der beiden kundenorientierten Lösungsanbieter wird es Eyelit ermöglichen, Fertigungssoftwarelösungen für eine breite Palette von Branchen bereitzustellen.

  • Im September 2022 unterzeichnete Siemens Digital Industries Software eine neue Original Equipment Manufacturer (OEM)-Partnerschaft mit Cybord.



  • Report Coverage
    Report Coverage

    Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

    Segment Covered
    Segment Covered

    This text is related
    to segments covered.

    Regional Scope
    Regional Scope

    North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

    Country Scope
    Country Scope

    This text is related
    to country scope.

    Frequently Asked Questions


    What is the estimated global market size for manufacturing execution system in life sciences market?

    The global manufacturing execution system in life sciences market was estimated to be US$ 3,139.14 million in 2022 and is expected to grow at a CAGR of 12.0%, during the forecast period 2023 - 2033.

    What are the driving factors impacting the global manufacturing execution system in life sciences market?

    Manufacturing execution system in life sciences market is being driven by the need for compliance with regulatory framework and requirement of accurate real-time data in production management process. Additionally, rising application in cell and gene therapy sector are expected to provide growth opportunities for the manufacturing execution system in life sciences market.

    What are the future trends for manufacturing execution system in life sciences market?

    Increasing shift from legacy to modern MES are expected to play a crucial role in the future of the manufacturing execution system in life sciences market. It helps enhance pharmaceutical industry production processes without requiring custom coding. Additionally, the fast and flexible responsiveness of the modern MES solution will make it easier to change production lines and accommodate small batches.

    Which are the key players holding the major market share of manufacturing execution system in life sciences market?

    The key players, holding majority shares, in manufacturing execution system in life sciences market includes Korber AG, Siemens AG, Emerson Electric, Rockwell Automation, and Dassault Systemes.

    Which is the fastest growing regional market?

    Asia Pacific is the fastest growing regional market, followed by Europe.

    Which countries are registering a high growth rate during the forecast period?

    India, China, and Germany are expected to register high growth rates during the forecast period.

    Which is the leading offering segment in the manufacturing execution system in life sciences market?

    The services segment led the manufacturing execution system in life sciences market with a significant share in 2022 and expected to be fastest growing.

    What will be the global market size for manufacturing execution system in life sciences market by 2033?

    The manufacturing execution system in life sciences market is expected to reach US$ 10,456.54 million by 2033.

    What is the incremental growth of the manufacturing execution system in life sciences market during the forecast period?

    The incremental growth, expected to be recorded for the manufacturing execution system in life sciences market during the forecast period, is US$ 7,083.22 million.

    The List of Companies - Manufacturing Execution System in Life Sciences Market 

    1. Korber AG
    2. Siemens AG
    3. Emerson Electric
    4. Schneider Electric
    5. Rockwell Automation
    6. Apprentice FS Inc
    7. ATS Global
    8. Atachi Systems
    9. LZ Lifescience Ltd
    10. POMS Corporation

    The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

    1. Data Collection and Secondary Research:

    As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

    Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

    1. Primary Research:

    The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

    For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

    A typical research interview fulfils the following functions:

    • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
    • Validates and strengthens in-house secondary research findings
    • Develops the analysis team’s expertise and market understanding

    Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

    • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
    • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

    Below is the breakup of our primary respondents by company, designation, and region:

    Research Methodology

    Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

    1. Data Analysis:

    Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

    • Macro-Economic Factor Analysis:

    We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

    • Country Level Data:

    Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

    • Company Profile:

    The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

    • Developing Base Number:

    Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

    1. Data Triangulation and Final Review:

    The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

    We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

    We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Related Reports